Tumor markers reveal which HER2+ breast cancer patients may respond to less intensive chemotherapy

The Journal of Clinical Oncology has published secondary results from the ECOG-ACRIN Cancer Research Group's CompassHER2-pCR objective proceedings (EA1181, NCT04266249). The findings assistance place which early-stage HER2-positive (HER2+) bosom cancers whitethorn beryllium astir apt to respond to little intensive chemotherapy than the existent standard.